Propanc Biopharma Files 8-K on Equity Sales & Amendments

TL;DR

Propanc Biopharma filed an 8-K detailing equity sales and corporate amendments.

AI Summary

Propanc Biopharma, Inc. filed an 8-K on November 10, 2025, reporting on events that occurred on November 4, 2025. The filing includes information on unregistered sales of equity securities, amendments to its articles of incorporation or bylaws, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive office is located in Camberwell, Victoria, Australia.

Why It Matters

This filing provides updates on Propanc Biopharma's corporate actions, including equity issuances and potential changes to its governing documents, which could impact its financial structure and operations.

Risk Assessment

Risk Level: medium — Filings related to unregistered equity sales and amendments to corporate documents can indicate potential dilution or changes in corporate governance, requiring closer investor scrutiny.

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Registrant
• November 4, 2025 (date) — Earliest event reported
• November 10, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• Australia (country) — Location of principal executive office

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PPCB The Nasdaq Stock Market LLC
• $10,000 — referred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash
• $1,000,099.00 — t share in exchange for cash payment of $1,000,099.00 to the Company. The shares of Series C
• $0.01 — ew series of preferred stock, par value $0.01 per share, designated as "Series C Pref
• $10,000 b — ch share of Series C Preferred Stock of $10,000 by the conversion price. The conversion p
• $5.00 — lesser of the fixed conversion price of $5.00 per share or 85% of the of the lowest t

Filing Documents

• form8-k.htm (8-K) — 40KB
• ex4-1.htm (EX-4.1) — 297KB
• ex4-1_001.jpg (GRAPHIC) — 32KB
• 0001493152-25-021567.txt ( ) — 609KB
• ppcb-20251104.xsd (EX-101.SCH) — 3KB
• ppcb-20251104_lab.xml (EX-101.LAB) — 33KB
• ppcb-20251104_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025, on October 7, 2025, Propanc Biopharma., Inc. (the " Company ") entered into a Securities Purchase Agreement (the "SPA") with Hexstone Capital LLC ("Hexstone") in connection with a private placement shares of Series C Preferred Stock ("Series C Preferred Stock"), subject to certain closing conditions. On November 4, 2025 the closing conditions under the SPA were completed and the company closed the transaction under the SPA, pursuant to which Hexstone purchased 100 shares of Series C Preferred Stock of the Company and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash payment of $1,000,099.00 to the Company. The shares of Series C Preferred Stock and the Warrant were issued pursuant to the private placement exemption from registration provided by Section 4(a)(2) of the Securities Act and/or by Rule 506 of Regulation D promulgated thereunder. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 4, 2025, the Company amended its Certificate of Incorporation and filed a Certificate of Designation with the Delaware Secretary of State that authorized the issuance of up to 9,900 shares of a new series of preferred stock, par value $0.01 per share, designated as "Series C Preferred Stock" for which the Board established the rights, preferences and limitations thereof. The Board authorized the Series C Preferred Stock pursuant to the authority given to the board of directors under the Certificate of Incorporation, which authorizes the issuance of up to ten million (10,000,000) shares of preferred stock, par value $0.01 per share, and authorizes the Board, by resolution, to establish any or all of the unissued shares of preferred stock, not then allo

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 10, 2025 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR